Bacainn Therapeutics

Bacainn Therapeutics Presents at ECCO ‘21 Results from Phase 1 Study that Shows BT051, an Oral, Locally-Acting Inhibitor of Neutrophil Trafficking and Activity, Is Safe and Well-Tolerated in Healthy Adults

Retrieved on: 
Friday, July 9, 2021
Biotechnology, FDA, Health, Pharmaceutical, Clinical trials, Medical specialties, Clinical medicine, Medicine, Autoimmune diseases, Abdominal pain, Colitis, Diarrhea, Ulcerative colitis, Inflammatory bowel disease, Biological therapy for inflammatory bowel disease, the Phase 1 Study, Bacainn Therapeutics, THE PHASE 1 STUDY, BACAINN THERAPEUTICS

People with IBD need additional therapeutic options as their disease progresses, said Chris Stevens, MD, Chief Medical Officer at Bacainn Therapeutics.

Key Points: 
  • People with IBD need additional therapeutic options as their disease progresses, said Chris Stevens, MD, Chief Medical Officer at Bacainn Therapeutics.
  • In this Phase 1 study, single-dose administration of BT051 was generally safe and well-tolerated with minimal systemic exposure, while BT051 stool concentrations were significantly above the predicted efficacy range.
  • Taken together, these data support the continued development of BT051 as a gut-targeted therapy for people with moderate-to-severe ulcerative colitis.
  • Bacainn Therapeutics is developing novel therapies that target the innate immune system to address uncontrolled inflammation in serious gastrointestinal and respiratory diseases.

Bacainn Therapeutics Reports Positive Topline Results from Phase 1 Study of BT051, a Novel Therapeutic Approach to Treat Inflammatory Diseases Such As Ulcerative Colitis

Retrieved on: 
Wednesday, December 2, 2020
Health, General Health, Clinical trials, Research, Science, Pharmaceutical, Biotechnology, Health sciences, Clinical research, Health, Medicine, Drug discovery, Pharmaceutical industry, Clinical trial, Design of experiments, Placebo, Upadacitinib, COVID-19 drug repurposing research, BT051, Bacainn Therapeutics

The completed clinical trial was a phase 1, randomized, double-blind, placebo-controlled, single-center study.

Key Points: 
  • The completed clinical trial was a phase 1, randomized, double-blind, placebo-controlled, single-center study.
  • The majority of adverse events were mild in severity, none lead to study discontinuation, and there were no serious adverse events reported.
  • Full results from the completed phase 1 clinical trial will be shared at a future scientific congress.
  • BT051 is a rationally designed new chemical entity which was discovered by Bacainn Therapeutics, Inc. to have activity limited to the GI tract.